In summary, our work firstly provides a novel BMSC-sEVs therapeutic on alleviating BBB disruption post-ischemic stroke and defines the mechanism is related to Cav-1 mediated autophagic degradation of tight junction protein ZO-1 and Occludin, contributing to the long-term neurological function amelioration. This evidence concerns the gene CAV1 and ischemic stroke.